Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment
Research on the multiple aspects of cognitive impairment in Down syndrome (DS), from genes to behavior to treatment, has made tremendous progress in the last decade. The study of congenital intellectual disabilities such as DS is challenging since they originate from the earliest stages of developme...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2017 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (179 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993546523304498 |
---|---|
ctrlnum |
(CKB)3800000000216309 (oapen)https://directory.doabooks.org/handle/20.500.12854/50412 (EXLCZ)993800000000216309 |
collection |
bib_alma |
record_format |
marc |
spelling |
Marie-Claude Potier auth Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment Intellectual Disabilities in Down Syndrome from Birth and throughout Life Frontiers Media SA 2017 1 electronic resource (179 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Research on the multiple aspects of cognitive impairment in Down syndrome (DS), from genes to behavior to treatment, has made tremendous progress in the last decade. The study of congenital intellectual disabilities such as DS is challenging since they originate from the earliest stages of development and both the acquisition of cognitive skills and neurodegenerative pathologies are cumulative. Comorbidities such as cardiac malformations, sleep apnea, diabetes and dementia are frequent in the DS population, as well, and their increased risk provides a means of assessing early stages of these pathologies that is relevant to the general population. Notably, persons with DS will develop the histopathology of Alzheimer’s disease (formation of neuritic plaques and tangles) and are at high risk for dementia, something that cannot be predicted in the population at large. Identification of the gene encoding the amyloid precursor protein, its localization to chromosome 21 in the 90’s and realization that all persons with DS develop pathology identified this as an important piece of the amyloid cascade hypothesis in Alzheimer’s disease. Awareness of the potential role of people with DS in understanding progression and treatment as well as identification of genetic risk factors and also protective factors for AD is reawakening. For the first time since DS was recognized, major pharmaceutical companies have entered the search for ameliorative treatments, and phase II clinical trials to improve learning and memory are in progress. Enriched environment, brain stimulation and alternative therapies are being tested while clinical assessment is improving, thus increasing the chances of success for therapeutic interventions. Researchers and clinicians are actively pursuing the possibility of prenatal treatments for many conditions, an area with a huge potential impact for developmental disorders such as DS. Our goal here is to present an overview of recent advances with an emphasis on behavioral and cognitive deficits and how these issues change through life in DS. The relevance of comorbidities to the end phenotypes described and relevance of pharmacological targets and possible treatments will be considerations throughout.Research on the multiple aspects of cognitive impairment in Down syndrome (DS), from genes to behavior to treatment, has made tremendous progress in the last decade. The study of congenital intellectual disabilities such as DS is challenging since they originate from the earliest stages of development and both the acquisition of cognitive skills and neurodegenerative pathologies are cumulative. Comorbidities such as cardiac malformations, sleep apnea, diabetes and dementia are frequent in the DS population, as well, and their increased risk provides a means of assessing early stages of these pathologies that is relevant to the general population. Notably, persons with DS will develop the histopathology of Alzheimer’s disease (formation of neuritic plaques and tangles) and are at high risk for dementia, something that cannot be predicted in the population at large. Identification of the gene encoding the amyloid precursor protein, its localization to chromosome 21 in the 90’s and realization that all persons with DS develop pathology identified this as an important piece of the amyloid cascade hypothesis in Alzheimer’s disease. Awareness of the potential role of people with DS in understanding progression and treatment as well as identification of genetic risk factors and also protective factors for AD is reawakening. For the first time since DS was recognized, major pharmaceutical companies have entered the search for ameliorative treatments, and phase II clinical trials to improve learning and memory are in progress. Enriched environment, brain stimulation and alternative therapies are being tested while clinical assessment is improving, thus increasing the chances of success for therapeutic interventions. Researchers and clinicians are actively pursuing the possibility of prenatal treatments for many conditions, an area with a huge potential impact for developmental disorders such as DS. Our goal here is to present an overview of recent advances with an emphasis on behavioral and cognitive deficits and how these issues change through life in DS. The relevance of comorbidities to the end phenotypes described and relevance of pharmacological targets and possible treatments will be considerations throughout. English Down Syndrome Intellectual Disabilities Treatment Language prenatal GABA Alzheimer's disease 2-88945-045-7 Roger H. Reeves auth |
language |
English |
format |
eBook |
author |
Marie-Claude Potier |
spellingShingle |
Marie-Claude Potier Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment Frontiers Research Topics |
author_facet |
Marie-Claude Potier Roger H. Reeves |
author_variant |
m c p mcp |
author2 |
Roger H. Reeves |
author2_variant |
r h r rhr |
author_sort |
Marie-Claude Potier |
title |
Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment |
title_full |
Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment |
title_fullStr |
Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment |
title_full_unstemmed |
Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment |
title_auth |
Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment |
title_alt |
Intellectual Disabilities in Down Syndrome from Birth and throughout Life |
title_new |
Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment |
title_sort |
intellectual disabilities in down syndrome from birth and throughout life: assessment and treatment |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2017 |
physical |
1 electronic resource (179 p.) |
isbn |
2-88945-045-7 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT marieclaudepotier intellectualdisabilitiesindownsyndromefrombirthandthroughoutlifeassessmentandtreatment AT rogerhreeves intellectualdisabilitiesindownsyndromefrombirthandthroughoutlifeassessmentandtreatment AT marieclaudepotier intellectualdisabilitiesindownsyndromefrombirthandthroughoutlife AT rogerhreeves intellectualdisabilitiesindownsyndromefrombirthandthroughoutlife |
status_str |
n |
ids_txt_mv |
(CKB)3800000000216309 (oapen)https://directory.doabooks.org/handle/20.500.12854/50412 (EXLCZ)993800000000216309 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1787548486011453440 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05706nam-a2200373z--4500</leader><controlfield tag="001">993546523304498</controlfield><controlfield tag="005">20231214132951.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2017 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3800000000216309</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/50412</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993800000000216309</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Marie-Claude Potier</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Intellectual Disabilities in Down Syndrome from Birth and throughout Life</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (179 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Research on the multiple aspects of cognitive impairment in Down syndrome (DS), from genes to behavior to treatment, has made tremendous progress in the last decade. The study of congenital intellectual disabilities such as DS is challenging since they originate from the earliest stages of development and both the acquisition of cognitive skills and neurodegenerative pathologies are cumulative. Comorbidities such as cardiac malformations, sleep apnea, diabetes and dementia are frequent in the DS population, as well, and their increased risk provides a means of assessing early stages of these pathologies that is relevant to the general population. Notably, persons with DS will develop the histopathology of Alzheimer’s disease (formation of neuritic plaques and tangles) and are at high risk for dementia, something that cannot be predicted in the population at large. Identification of the gene encoding the amyloid precursor protein, its localization to chromosome 21 in the 90’s and realization that all persons with DS develop pathology identified this as an important piece of the amyloid cascade hypothesis in Alzheimer’s disease. Awareness of the potential role of people with DS in understanding progression and treatment as well as identification of genetic risk factors and also protective factors for AD is reawakening. For the first time since DS was recognized, major pharmaceutical companies have entered the search for ameliorative treatments, and phase II clinical trials to improve learning and memory are in progress. Enriched environment, brain stimulation and alternative therapies are being tested while clinical assessment is improving, thus increasing the chances of success for therapeutic interventions. Researchers and clinicians are actively pursuing the possibility of prenatal treatments for many conditions, an area with a huge potential impact for developmental disorders such as DS. Our goal here is to present an overview of recent advances with an emphasis on behavioral and cognitive deficits and how these issues change through life in DS. The relevance of comorbidities to the end phenotypes described and relevance of pharmacological targets and possible treatments will be considerations throughout.Research on the multiple aspects of cognitive impairment in Down syndrome (DS), from genes to behavior to treatment, has made tremendous progress in the last decade. The study of congenital intellectual disabilities such as DS is challenging since they originate from the earliest stages of development and both the acquisition of cognitive skills and neurodegenerative pathologies are cumulative. Comorbidities such as cardiac malformations, sleep apnea, diabetes and dementia are frequent in the DS population, as well, and their increased risk provides a means of assessing early stages of these pathologies that is relevant to the general population. Notably, persons with DS will develop the histopathology of Alzheimer’s disease (formation of neuritic plaques and tangles) and are at high risk for dementia, something that cannot be predicted in the population at large. Identification of the gene encoding the amyloid precursor protein, its localization to chromosome 21 in the 90’s and realization that all persons with DS develop pathology identified this as an important piece of the amyloid cascade hypothesis in Alzheimer’s disease. Awareness of the potential role of people with DS in understanding progression and treatment as well as identification of genetic risk factors and also protective factors for AD is reawakening. For the first time since DS was recognized, major pharmaceutical companies have entered the search for ameliorative treatments, and phase II clinical trials to improve learning and memory are in progress. Enriched environment, brain stimulation and alternative therapies are being tested while clinical assessment is improving, thus increasing the chances of success for therapeutic interventions. Researchers and clinicians are actively pursuing the possibility of prenatal treatments for many conditions, an area with a huge potential impact for developmental disorders such as DS. Our goal here is to present an overview of recent advances with an emphasis on behavioral and cognitive deficits and how these issues change through life in DS. The relevance of comorbidities to the end phenotypes described and relevance of pharmacological targets and possible treatments will be considerations throughout.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Down Syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Intellectual Disabilities</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Language</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prenatal</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">GABA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Alzheimer's disease</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-045-7</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roger H. Reeves</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:38:26 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2017-09-30 19:47:25 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338269490004498&Force_direct=true</subfield><subfield code="Z">5338269490004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338269490004498</subfield></datafield></record></collection> |